Acotinib/Acalatinib Global Price Analysis in 2024

Acalabrutinib, also known as acalabrutinib (Acalabrutinib), is an advanced irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor. Compared with ibrutinib, it inhibits BTK more selectively at the covalent level, thus showing significant effects in the treatment of B-cell malignancies, such as refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).

Acotinib is a prescription drug, and its treatment process needs to be guided and monitored by an experienced cancer doctor. Usually taken as an oral capsule, the recommended daily dose is 200 mg in two divided doses. Treatment continues as long as the condition is stably controlled and the patient does not experience intolerable side effects. However, dose adjustment or treatment interruption may be necessary if severe side effects occur or if certain medications are taken concurrently.

Concerning the price of acotinib, there are significant differences between markets and product sources. Overseas, the price of 60 tablets of 100 mg of the original drug may exceed US$10,000, highlighting its high-end pricing strategy. Fortunately, products with the same specifications are already on the market in China and have been included in the Category B medical insurance catalog. In China, the price of each box of 100 mg and 56 pills is about RMB 40,000, but medical insurance reimbursement is limited to patients who meet the indications.

In addition, generic versions of acotinib have appeared in overseas markets and have begun sales. The active ingredients of these generic drugs are highly similar to the brand-name drugs. For example, a box of 100mg*60 generic medicines produced by a pharmaceutical company in Laos sells for about more than 3,000 yuan. However, please note that this price may fluctuate due to exchange rate changes. For more information or consultation on overseas drug prices, please contact the professional consultants of Yaode Medicine.